Phase 2 Clinical Trial Data for WTX101 Published in The Lancet Gastroenterology & Hepatology
Wilson Therapeutics (publ.) today announced that data from a Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational oral first-in-class copper-protein-binding agent for the treatment of patients with Wilson Disease, has been published online in The Lancet Gastroenterology & Hepatology and will be available in print in the December issue. The results show that treatment with WTX101 induces rapid copper control, significantly reducing free copper levels by 72% from baseline after approximately 3 months, and is associated with significant early improvements in
According to Tomi Takala, development work at Kiilto is a continuous, ongoing process.Last week, I heard one of our customers thanking our Regional Manager for Kiilto's contribution to their core operations—and not for the first time. The Kiilto laboratory had developed a more functional solution for this customer's process. The result was an even higher-quality end product that could be produced more efficiently than before.
These kinds of achievements are what our work is all about. It benefits both partners when our customer's everyday operations become more efficient and adds a
